主要目的：比较空腹给药条件下，湖南派格兰药业有限公司提供的双氯芬酸二乙胺乳胶剂（规格：2.32%（50 g：1.16 g，以C18H22Cl2N2O2计））与Haleon UK Trading Limited持证的双氯芬酸二乙胺乳胶剂（商品名：Voltarol®；规格：2.32%（50 g：1.16 g，以C18H22Cl2N2O2计））在中国健康人群吸收程度和吸收速度的差异。次要目的：评价空腹给药条件下，湖南派格兰药业有限公司提供的双氯芬酸二乙胺乳胶剂（规格：2.32%（50 g：1.16 g，以C18H22Cl2N2O2计））与Haleon UK Trading Limited持证的双氯芬酸二乙胺乳胶剂（商品名：Voltarol®；规格：2.32%（50 g：1.16 g，以C18H22Cl2N2O2计））在中国健康人群体内的安全性。

[Translation]

Main purpose: To compare the differences in absorption degree and absorption rate of diclofenac diethylamine emulsion (specification: 2.32% (50 g: 1.16 g, calculated as C18H22Cl2N2O2)) provided by Hunan Paiglan Pharmaceutical Co., Ltd. and diclofenac diethylamine emulsion (trade name: Voltarol®; specification: 2.32% (50 g: 1.16 g, calculated as C18H22Cl2N2O2)) certified by Haleon UK Trading Limited in healthy Chinese population under fasting administration conditions. Secondary objective: To evaluate the safety of diclofenac diethylamine emulsion (specification: 2.32% (50 g: 1.16 g, calculated as C18H22Cl2N2O2)) provided by Hunan Paiglan Pharmaceutical Co., Ltd. and diclofenac diethylamine emulsion (trade name: Voltarol®; specification: 2.32% (50 g: 1.16 g, calculated as C18H22Cl2N2O2)) certified by Haleon UK Trading Limited in healthy Chinese population under fasting conditions.

Start Date04 May 2025

Sponsor / Collaborator

Hunan Paiglan Pharmaceutical Co., Ltd.

CTR20250711

/ Active, not recruitingNot Applicable

双氯芬酸二乙胺乳胶剂在中国成年健康受试者中的一项单中心、随机、开放、空腹、单次给药、两制剂、三序列、三周期、部分重复交叉生物等效性研究

[Translation] A single-center, randomized, open-label, fasting, single-dose, two-formulation, three-sequence, three-period, partially repeated crossover bioequivalence study of diclofenac diethylamine emulsion in healthy adult Chinese subjects

主要研究目的：考察空腹单次外用受试制剂双氯芬酸二乙胺乳胶剂（规格：1%[20g: 0.2g]，华益泰康药业股份有限公司生产，海南天盛保和生物科技有限公司提供）与参比制剂双氯芬酸二乙胺乳胶剂（商品名：扶他林®，规格：1%[20g: 0.2g]，GSK Consumer Healthcare Schweiz AG持证，GSK Consumer Healthcare SARL生产，海南天盛保和生物科技有限公司提供）在中国成年健康受试者体内的药代动力学特征，评价空腹状态下外用两种制剂的生物等效性。次要研究目的：评价空腹单次外用受试制剂和参比制剂在中国成年健康受试者中的安全性。

[Translation]

Main study objectives: To investigate the pharmacokinetic characteristics of the single-dose topical test preparation diclofenac diethylamine emulsion (specification: 1% [20g: 0.2g], produced by Huayi Taikang Pharmaceutical Co., Ltd., provided by Hainan Tiansheng Baohe Biotechnology Co., Ltd.) and the reference preparation diclofenac diethylamine emulsion (trade name: Voltaren®, specification: 1% [20g: 0.2g], licensed by GSK Consumer Healthcare Schweiz AG, produced by GSK Consumer Healthcare SARL, provided by Hainan Tiansheng Baohe Biotechnology Co., Ltd.) in healthy adult Chinese subjects, and to evaluate the bioequivalence of the two topical preparations in the fasting state. Secondary study objectives: To evaluate the safety of the single-dose topical test preparation and the reference preparation in healthy adult Chinese subjects.

Start Date25 Feb 2025

Sponsor / Collaborator

Hainan Tiansheng Baohe Biotechnology Co., Ltd.

CTR20244293

/ CompletedNot Applicable

双氯芬酸二乙胺乳胶剂在中国健康人群中外用条件下单次给药的人体生物等效性临床试验方案

[Translation] A human bioequivalence clinical trial protocol for a single-dose topical administration of diclofenac diethylamine emulsion in healthy Chinese people

主要目的：以持证商为GSK Consumer Healthcare Schweiz AG 的双氯芬酸二乙胺乳胶剂，规格：1%（20g:0.2g，以双氯芬酸钠计））为参比制剂，以青岛百洋制药有限公司研发的双氯芬酸二乙胺乳胶剂（1%（20g:0.2g，以双氯芬酸钠计））为受试制剂，评价两种制剂在中国健康受试者中外用条件下的生物等效性。次要目的：1）评价受试制剂与参比制剂在中国健康受试者中的安全性；2）评价受试制剂与参比制剂对中国健康受试者的皮肤反应性。

[Translation]

Primary objective: To evaluate the bioequivalence of the two preparations under topical conditions in healthy Chinese subjects, using diclofenac diethylamine emulsion (specification: 1% (20g:0.2g, calculated as diclofenac sodium)) from GSK Consumer Healthcare Schweiz AG as the reference preparation and diclofenac diethylamine emulsion (1% (20g:0.2g, calculated as diclofenac sodium)) developed by Qingdao Baiyang Pharmaceutical Co., Ltd. as the test preparation. Secondary objectives: 1) To evaluate the safety of the test preparation and the reference preparation in healthy Chinese subjects; 2) To evaluate the skin reactivity of the test preparation and the reference preparation in healthy Chinese subjects.

Start Date13 Dec 2024

Sponsor / Collaborator

Qingdao Guofeng Group Huayang Parmaceutical Co. Ltd.

100 Clinical Results associated with Diclofenac Diethylamine

100 Translational Medicine associated with Diclofenac Diethylamine

100 Patents (Medical) associated with Diclofenac Diethylamine

243

Literatures (Medical) associated with Diclofenac Diethylamine

01 Nov 2024·CURRENT MOLECULAR MEDICINE

Hypothesizing the Oleic Acid-Mediated Enhanced and Sustained Transdermal Codelivery of Pregabalin and Diclofenac Adhesive Nanogel: A Proof of Concept

Article

Author: Singh, Snigdha ; Noor, Afeefa ; Kohli, Kanchan ; Datta, Deepanjan ; Rathee, Anjali

Pregabalin (PG) and diclofenac diethylamine (DEE) are anti-inflammatory molecules that are effective in relieving inflammation and pain associated with musculoskeletal disorders, arthritis, and post-traumatic pain, among others. Intravenous and oral delivery of these two molecules has their limitations. However, the transdermal route is believed to be an alternate viable option for the delivery of therapeutic molecules with desired physicochemical properties. To this end, it is vital to understand the physicochemical properties of these drugs, dosage, and strategies to enhance permeation, thereby surmounting the associated constraints and concurrently attaining a sustained release of these therapeutic molecules when administered in combination. The present work hypothesizes the enhanced permeation and sustained release of pregabalin and diclofenac diethylamine across the skin, entrapped in the adhesive nano-organogel formulation, including permeation enhancers. The solubility studies of pregabalin and diclofenac diethylamine in combination were performed in different permeation enhancers. Oleic acid was optimized as the best permeation enhancer based on in vitro studies. Pluronic organogel containing pregabalin and diclofenac diethylamine with oleic acid was fabricated. Duro-Tak® (87-2196) was added to the organogel formulation as a pressure-sensitive adhesive to sustain the release profile of these two therapeutic molecules. The adhesive organogel was characterized for particle size, scanning electron microscopy, and contact angle measurement. The HPLC method developed for the quantification of the dual drug showed a retention time of 3.84 minutes and 9.69 minutes for pregabalin and diclofenac, respectively. The fabricated nanogel adhesive formulation showed the desired results with particle size and contact angle of 282 ± 57 nm and ≥120⁰, respectively. In vitro studies showed the percentage cumulative release of 24.90 ± 4.65% and 33.29 ± 4.81% for pregabalin and diclofenac, respectively. In order to accomplish transdermal permeation, the suggested hypothesis of fabricating PG and DEE nano-organogel in combination with permeation enhancers will be a viable drug delivery method. In comparison to a traditional gel formulation, oleic acid as a permeation enhancer increased the penetration of both PG and DEE from the organogel formulation. Notably, the studies showed that the use of pressure-sensitive adhesives enabled the sustained release of both PG and DEE.Therefore, the results anticipated the hypothesis that the transdermal delivery of adhesive PG and DEEbased nanogel across the human skin can be achieved to inhibit inflammation and pain.

01 Sep 2024·JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY

In vitro evaluation of ethyl cellulose and polyvinyl pyrrolidone composite nanofibers for transdermal delivery of diclofenac diethylamine

Author: Akhgari, Abbas ; Abbaspour, Mohammad Reza ; Sadeghi, Fatemeh ; Hatami, Hooman ; Kariznavi, Elnaz ; Garekani, Hadi Afrasiabi ; Nokhodchi, Ali

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most prominent painkiller and anti-inflammatory drugs with gastrointestinal (GI) adverse effects.Transdermal drug delivery systems (TDDS) could overcome GI adverse effects associated with oral ingestion of NSAIDs as well as maintaining a prolonged release of the drug.The main aim of this study was to prepare and investigate diclofenac diethylamine (DDA) loaded nanofibers made of Et cellulose (EC) and polyvinyl pyrrolidone K90 (PVP) using electrospinning.The impact of penetration enhancers such as nerolidol and farnesol on release profiles through cellophane membranes and other characteristics of nanofibers were also investigated.Based on release studies, some formulations were selected for release examination through rate skin using Franz diffusion cells.To gain insight about potential interactions between drug and polymers FTIR, DSC, and XRD analyses were performed.Morphol. examination was also conducted using SEM (SEM).Morphol. studies showed that nanofibers made of EC only are greater in the mean diameter than other nanofibers while other formulations were not significantly different from each other regardless of the presence of penetration enhancers.EC nanofibers had the lowest elastic modulus and tensile strength and most elongation at break which makes them the least tough and most flexible nanofibers among all the formulations.The addition of PVP increased the toughness and decreased the flexibility of nanofibers.The addition of nerolidol did not alter the mech. properties of nanofibers significantly, while the addition of farnesol increased elastic modulus, tensile strength, and elongation at break significantly in a concentration-dependent manner.EC nanofibers had the lowest release rate and lowest total cumulative release content while the addition of PVP significantly improved both of these features.In release studies through cellophane membrane, the addition of 5 % of penetration enhancer slightly increased the release rate while did not significantly alter cumulative release while the addition of 10 % farnesol notably increased the release rate and total cumulative released content.Release studies through rat skin were in accordance with cellophane membrane studies and the formulation with 10 % farnesol had the most release rate and total cumulative release and these findings confirm the pos. effect of penetration enhancers.DSC thermogram showed an amorphous state of the drug in fibers and this was supported by XRD results.The FTIR results confirmed that no chem. interaction between the drug and other formulation components has occurred and no new compounds have been formed.Based on these results, the utilization of DDA-loaded PVP and EC nanofibers in conjunction with a penetration enhancer showed significant potential for application in transdermal patches.

27 May 2024·Journal of drug targeting

Preparation and anti-inflammatory effect of mercury sulphide nanoparticle-loaded hydrogels

Article

Author: Lv, Wei ; Xuan, Chengrui ; Wang, Can ; Li, Jian ; Liang, Ruming ; Wu, Shikui ; Yang, Yihang

We successfully prepared mercury sulphide nanoparticle hydrogels by physical encapsulation method. The successfully prepared mercuric sulphide nanoparticle hydrogel was a zinc folate hydrogel, which showed an obvious porous structure with interconnected and uniformly distributed pores and a pore size range of about 20 μm. The maximum drug loading of the hydrogels was 3%, and the in vitro cumulative release degree was in accordance with the first-order kinetic equation Mt = 149.529 (1 - e^-0.026^t). The particles in mercuric sulphide nanoparticle hydrogels significantly down-regulated the expression of the cell surface co-stimulatory molecule CD86 (p < .0001). Meanwhile, the inflammatory response was regulated through the NF-κB pathway in LPS-induced inflammatory cells. Later, it was observed that mercuric sulphide nanoparticle hydrogels could significantly counteract the inflammatory and immune models through a mouse ear swelling model, a rat foot-plantar swelling model and a rheumatoid arthritis model. This design targets the immunomodulatory, and anti-inflammatory effects through nanocomposite hydrogel technology. It reduces the drawbacks of low mercury utilisation and susceptibility to accumulation of toxicity. It aims to provide an experimental basis for the development of mercuric sulphide and the treatment of inflammatory and immune-related diseases.HighlightsMercury sulphide nanoparticle hydrogel has an optimal mercury sulphide nanoparticle content of 2%, is structurally homogeneous and stable, and does not exhibit significant liver or kidney toxicity.Mercuric sulphide nanoparticle hydrogel exerts anti-inflammatory effects in cells and rats, and regulates the expression of macrophage surface molecules and factors related to the NF-κB pathway.Mercuric sulphide nanoparticle hydrogel improves the condition of ankle synovial joints in a rat model of rheumatoid arthritis.

News (Medical) associated with Diclofenac Diethylamine

06 Nov 2024

·pharma.economictimes.indiatimes.com

Paracetamol to PAN-D: CDSCO finds over 50 sub-standard drugs. Check full list of medicines

New Delhi: The Central Drugs Standard Control Organisation ( CDSCO ) has identified over 50 drugs which have failed in the drug test. In its latest report, the controller said 50 drugs including Paracetamol are "not of standard quality" (NSQ). The report has also flagged calcium and vitamin D3 supplements, anti-diabetes pills, and high blood pressure medicines. Paracetamol tablets from Karnataka Antibiotics & Pharmaceuticals Ltd were specifically mentioned for quality concerns. The report listed a total of 48 drugs in the NSQ category, including a Gauze Roll Non Sterile Roller Bandage. NSQ alerts come from monthly random sampling conducted by state drug officers. Some of the medicines were produced by companies like Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), Karnataka Antibiotics & Pharmaceuticals Ltd, Meg Lifesciences, and Pure & Cure Healthcare. Additionally, the CDSCO shared another list that features five more drugs that failed quality tests. The pharmaceutical companies denied responsibility for these drugs. They claim they are "spurious," and one response from a company stated, "The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. The product is purported to be spurious; however, the same is subjected to outcome of investigation." CDSCO NSQ Test: Full list of drugs and their manufacturers Here is the list of drugs that failed the CDSCO test along with the manufacturers: Amoxicillin And Potassium Clavulanate Tablets IP (Clavam 625) - M/s. Alkem Health Science Amoxicillin & Potassium Clavulanate Tablets (Mexclav 625) - M/s. Meg Lifesciences Calcium And Vitamin D3 Tablets IP (Shelcal 500) - M/s. Pure & Cure Healthcare Pvt. Ltd. Metformin Hydrochloride Sustained-release Tablets IP (Glycimet-SR-500) - M/s. Scott-Edil Pharmacia Ltd. Vitamin B Complex with Vitamin C Softgels - M/s. Asoj Soft Caps Pvt. Ltd. Rifmin 550 (Rifaximin Tablets 550 mg) - M/s. Legen Healthcare Pantoprazole Gastro-Resistant and Domperidone Prolonged-Release Capsules IP (Pan - D) - M/s. Alkem Health Science Paracetamol Tablets IP 500 mg - M/s. Karnataka Antibiotics and Pharmaceuticals Ltd. Montair LC Kid (Montelukast Sodium & Levocetirizine Hydrochloride Dispersible Tablets) - M/s. Pure & Cure Healthcare Pvt. Ltd. Compound Sodium Lactate Injection IP (Ringer Lactate Solution for Injection) (RL 500 ml) - M/s. Vision Parenteral Pvt. Ltd. Fexofenadine Hydrochloride Tablets IP 120 mg - M/s. Maxtar Bio-Genics Laxnorm Solution (Lactulose Solution USP) - M/s. Athens Life Sciences Heparin Sodium Injection 5000 Units (Hostranil Injection) - M/s. Health Biotech Ltd. Buflam Forte Suspension (Ibuprofen & Paracetamol Oral Suspension) - M/s. Ornate Pharma Pvt. Ltd. Cepodem XP 50 Dry Suspension (Cefpodoxime Proxetil and Potassium Clavulanate Oral Suspension) - M/s. Hetero Labs Limited Nimesulide, Paracetamol and Chlorzoxazone Tablets (NICIP MR) - M/s. HSN International Rolled Gauze (Non-Sterilized) - M/s. Blazon India Ciprofloxacin Tablets IP 500 mg (Ocif-500) - M/s. Ornate Labs Pvt. Ltd. Nimesulide, Phenylephrine Hydrochloride & Levocetirizine Dihydrochloride Tablets (Nunim-Cold) - M/s. Unispeed Pharmaceuticals Pvt. Ltd. Adrenaline Injection IP Sterile 1 ml - M/s. Alves Healthcare Pvt. Ltd. Compound Sodium Lactate Injection IP (Ringer Lactate Solution for Injection) RL 500ml - M/s. Vision Parentral Pvt. Ltd. Vingel XL Pro Gel (Diclofenac Diethylamine, Linseed Oil, Methyl Salicylate, and Menthol Gel) - M/s. Universal Twin Labs Atropine Sulphate Injection IP 2 ml - M/s. Nandani Medical Laboratories Pvt. Ltd. Cefoperazone & Sulbactam For Injection (Todaycef 1.5 G) - M/s. Daxin Pharmaceuticals Pvt. Ltd. Heparin Sodium Injection IP 25000 IU / 5ml - M/s. Scott-Edil Pharmacia Ltd. Cefepime & Tazobactam for Injection (Crupime - TZ Kid Injection) - M/s. Cosmas Research Lab. Ltd. Atropine Sulphate Injection IP (Atropine Sulphate) - M/s. Priya Pharmaceuticals Salbutamol, Bromhexine HCI, Guaifenesin and Menthol Syrup (Acozil Expectorant) - M/s. Antila Lifesciences Pvt. Ltd. Diclofenac Sodium IP - M/s. Sara Exports Ltd. Escitalopram and Clonazepam Tablets IP (Klozaps-ES Tablets) - M/s. Digital Vision Phenytoin Sodium Injection USP - M/s. Health Biotech Ltd. Paracetamol, Phenylephrine Hydrochloride and Cetirizine Hydrochloride Suspension (Cethel Cold DS Suspension) - M/s. Win Cure Pharma Calcium 500 mg with Vitamin D3 250 IU Tablets IP - M/s. Life Max Cancer Laboratories Amoxycillin and Potassium Clavulanate Tablets IP 625 mg (Renamega- CV 625) - M/s. Malik Lifesciences Pvt. Ltd. Olmesartan Medoxomil Tablets IP 40 mg - M/s. Life Max Cancer Laboratories INFUSION SET-NV - M/s. Medivision Healthcare Telmisartan Tablets IP 40 mg - M/s. Life Max Cancer Laboratories Alprazolam Tablets IP 0.25 mg (Erazol-0.25 Tablets) - M/s. Elikem Pharmaceuticals Pvt. Ltd. Glimepiride Tablets IP (2 mg) - M/s. Mascot Health Series Pvt. Ltd. Calcium and Vitamin D3 Tablets IP - M/s. Unicure India Ltd. Metronidazole Tablets IP 400mg - M/s. Hindustan Antibiotics Ltd. Paziva -40 - M/s. Gnosis Pharmaceuticals Pvt. Ltd. Pantomed -40 - Digital Vision 176 Cefixime Oral Suspension IP (Dry Syrup) - Nestor Pharmaceuticals Ltd. Moxymed CV - Alexa Pharmaceuticals Frusemide Injection IP 20 mg - Nestor Pharmaceuticals Ltd. Kudajarishtam - Bala Herbals Tab Nodosis - Steadfast Medishield Pvt. Ltd. Haridrakhanda - Bhaskara Vilasam Vaidyasala Pantoprazole Inj. BP 40 mg - Kerala Medical Services Corporation Ltd. Yogaraja Guggulu - Bhaskara Vilasam Vaidyasala PANCEF-OF - Aglomed Ltd.

Drug Approval

100 Deals associated with Diclofenac Diethylamine

External Link

KEGG	Wiki	ATC	Drug Bank
D07817	Diclofenac Diethylamine	M02AA15 D11AX18 M01AB05	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Inflammation	China	-	01 Jan 1999
Pain	China	-	01 Jan 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Arthralgia	Phase 3	China	NOVARTIS CONSUMER HEALTH SCHWEIZ AG	24 Oct 2019
Arthralgia	Phase 3	China	Novartis Consumer Health SA	24 Oct 2019
Arthralgia	Phase 3	China	Beijing Novartis Pharma Co. Ltd.	24 Oct 2019
Contusions	Phase 3	China	NOVARTIS CONSUMER HEALTH SCHWEIZ AG	24 Oct 2019
Contusions	Phase 3	China	Beijing Novartis Pharma Co. Ltd.	24 Oct 2019
Contusions	Phase 3	China	Novartis Consumer Health SA	24 Oct 2019
Osteoarthritis	Phase 3	China	NOVARTIS CONSUMER HEALTH SCHWEIZ AG	24 Oct 2019
Osteoarthritis	Phase 3	China	Beijing Novartis Pharma Co. Ltd.	24 Oct 2019
Osteoarthritis	Phase 3	China	Novartis Consumer Health SA	24 Oct 2019
Osteoarthritis, Knee	Phase 3	Germany	Novartis AG	01 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04052620 (Pubmed)	Phase 3	-	302	Diclofenac diethylamine 2.32% gel	tufuhejmar(ccvxapttmx): mean difference = 1.11, P-Value = 0.595 View more	Positive	24 Dec 2022
				Diclofenac diethylamine 1.16% gel
NCT04052620 (CTgov)	Phase 3	Pain \| Ankle Injuries	313	Diclofenac diethylamine 1.16% gel	rbcbzzynlb(waglnitqlb) = slldrptyjq cblucosrno (kdlxxtcyzu, 1.45) View more	-	12 Apr 2022
NCT03497039 (CTgov)	Phase 1	Pain \| Osteoarthritis \| Osteoarthritis, Knee	47	Diclofenac Diethylamine (DDEA) (Diclofenac Diethylamine (DDEA) Gel)	zplrlqnmqr(bigowxpmby) = xnbvsfxrlb aziumbgpyv (nzcksewskx, euxdmxccvr - jbpugivgnp) View more	-	24 Feb 2020
				Placebo (Placebo Gel)	zplrlqnmqr(bigowxpmby) = noerebyiki aziumbgpyv (nzcksewskx, nehukgkwvr - znlyuqthcx) View more
NCT01967550 (CTgov)	Phase 3	Osteoarthritis, Knee	304	diclofenac diethylamine, DDEA 2.32% gel (Diclofenac Diethylamine, DDEA 2.32% Gel)	ylnjpqoqrw(liripqxdee) = puznqbvvvc wglgmcqehj (lnexvctvzj, 23.8) View more	-	03 Jun 2015
				Placebo (Placebo)	ylnjpqoqrw(liripqxdee) = hbdrotwrio wglgmcqehj (lnexvctvzj, 23.5) View more
NCT01335724 (Pubmed \| BMC Musculoskelet Disord)	Phase 4	Neck Pain	72	Diclofenac diethylamine 1.16% gel	qfboqoteet(fxmhrpkmyt) = qverzxyikc fmdhinnkaq (qmccpcohmt ) View more	Positive	21 Aug 2013
				Placebo gel	qfboqoteet(fxmhrpkmyt) = ymmgkpxbpa fmdhinnkaq (qmccpcohmt ) View more
NCT01335724 (CTgov)	Phase 4	Neck Pain	72	Diclofenac diethylamine 1.16% gel (Diclofenac Diethylamine 1.16% Gel)	iwkykcpeip(lqkrhjkphq) = twocjqtgos wjhuxeeoul (bfhrmpmtpe, 12.9) View more	-	18 Jul 2012
				Placebo gel (Placebo Gel)	iwkykcpeip(lqkrhjkphq) = xdbraijdiu wjhuxeeoul (bfhrmpmtpe, 16.1) View more
NCT00955513 (CTgov)	Phase 3	Ankle Injuries	242	Diclofenac Diethylamine (Diclofenac Diethylamine Gel 2.32% Gel. Applied 2 Times a Day)	enwevksaeq(sffcgmceuz) = zjhxenxxkr iucpqyqvzp (pztrymchet, 19.3) View more	-	26 Jan 2011
				Diclofenac Diethylamine (Diclofenac Diethylamine Gel 2.32% Gel. Applied 3 Times a Day)	enwevksaeq(sffcgmceuz) = cppkpiyzyt iucpqyqvzp (pztrymchet, 21.5) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis